Task order title: contract orientation and kickoff meeting, task order period of performance: 1/25/2019-2/24/2019.
Ended Awarded Last action
- Contract number
- 75N91019F00129
- Awardee
-
University Of Oklahoma UEI GY8NMUZQXVS7 Part of University Of Oklahoma
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,997
Award facts
- Opportunity
-
- PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Biomarker Endpoints, Preclinical Services for Biopharmaceutical Product Development and Manufacturing, and Toxicology and Pharmacology Testing Pre-Solicitation · N01CN7701918 · Posted Apr 19, 2018
- PREVENT Cancer Preclinical Drug Development Program Award Notice · Posted May 7, 2018
- Contract value 100% obligated
- $1,997.35 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 7 offers Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Oklahoma City, OK 73104, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$1,503 | |
| Original award | $3,500 |
About this award
This federal contract award is a $2,000 delivery order issued against the PREVENT Preclinical Drug Development Program master IDIQ by the National Cancer Institute. The University of Oklahoma Health Sciences Center, as prime contractor, will provide contract orientation and kickoff meeting services from January to February 2019 in Oklahoma City. The purpose of the PREVENT program, managed by the National Institutes of Health, is to support preclinical efficacy testing of novel cancer prevention and treatment agents. No set aside designation or major subcontractors are indicated. The funding agency, HHS's National Cancer Institute, aims to accelerate development of innovative approaches that could reduce cancer incidence, progression, and mortality.
Quick answers
Who was awarded contract 75N91019F00129?
75N91019F00129 was awarded to University Of Oklahoma by National Cancer Institute (National Institutes of Health) on January 24, 2019.
How much is contract 75N91019F00129 worth?
The government has obligated $1,997 on 75N91019F00129.
Is contract 75N91019F00129 an order under another contract?
Yes. 75N91019F00129 is a delivery order under 75N91019D00020, an indefinite delivery contract, on PREVENT Preclinical Drug Development Program (PREVENT).
Was contract 75N91019F00129 competed?
The extent of competition for 75N91019F00129 was full and open competition. The government received 7 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award